

# Lars Forsgren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5486726/publications.pdf>

Version: 2024-02-01

40  
papers

2,101  
citations

304602

22  
h-index

315616

38  
g-index

40  
all docs

40  
docs citations

40  
times ranked

4433  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1569-1578.	1.5	5
2	Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. <i>Neurology</i> , 2021, 96, e1036-e1044.	1.5	17
3	Balance and mobility in patients with newly diagnosed Parkinson's disease – a five-year follow-up of a cohort in northern Sweden. <i>Disability and Rehabilitation</i> , 2020, 42, 770-778.	0.9	11
4	Activities of daily living in Parkinson's disease: Time/gender perspective. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 168-176.	1.0	23
5	The Effects of Working Memory Updating Training in Parkinson's Disease: A Feasibility and Single-Subject Study on Cognition, Movement and Functional Brain Response. <i>Frontiers in Psychology</i> , 2020, 11, 587925.	1.1	4
6	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , 2019, 48, 912-925.	0.9	70
7	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 158-165.	1.1	12
8	Î±-synuclein~lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15226-15235.	3.3	33
9	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
10	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 202-210.	1.1	27
11	General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 98-104.	1.1	7
12	Deep brain stimulation in the caudal zona incerta versus best medical treatment in patients with Parkinson's disease: a randomised blinded evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 710-716.	0.9	59
13	Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 86-92.	0.6	21
14	Early predictors of mortality in parkinsonism and Parkinson disease. <i>Neurology</i> , 2018, 91, e2045-e2056.	1.5	111
15	Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1293-1301.	0.4	23
16	Moist smokeless tobacco (Snus) use and risk of Parkinson's disease. <i>International Journal of Epidemiology</i> , 2017, 46, dyw294.	0.9	14
17	Fractional Anisotropy and Mean Diffusion as Measures of Dopaminergic Function in Parkinson's Disease: Challenging Results. <i>Journal of Parkinson's Disease</i> , 2017, 7, 129-142.	1.5	11
18	Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 41-47.	1.1	66

#	ARTICLE	IF	CITATIONS
19	Immunochemical Detection of $\alpha$ -Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1170-1176.	1.7	52
20	PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study. <i>Journal of the Neurological Sciences</i> , 2017, 381, 278-284.	0.3	8
21	The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal. <i>Neuroscience Letters</i> , 2017, 658, 48-52.	1.0	57
22	How long for epilepsy remission in the ILAE definition?. <i>Epilepsia</i> , 2017, 58, 1486-1487.	2.6	4
23	Low frequency of GCH1 and TH mutations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 109-111.	1.1	5
24	NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. <i>Metabolomics</i> , 2016, 12, 1.	1.4	23
25	Rare variants in dementia genes and Parkinson's disease. <i>European Journal of Human Genetics</i> , 2016, 24, 1661-1662.	1.4	0
26	Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden. <i>Neurobiology of Aging</i> , 2016, 45, 212.e5-212.e11.	1.5	50
27	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 34-39.	1.7	60
28	Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. <i>Journal of Human Genetics</i> , 2015, 60, 357-362.	1.1	51
29	Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea. <i>JAMA Internal Medicine</i> , 2015, 175, 1278.	2.6	64
30	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.4	152
31	NMR metabolomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls. <i>Neuroscience Letters</i> , 2015, 594, 36-39.	1.0	50
32	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1175.	4.5	148
33	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 549-560.	1.5	99
34	Weight gain and increased central obesity in the early phase of Parkinson's disease. <i>Clinical Nutrition</i> , 2014, 33, 1132-1139.	2.3	57
35	A Generic Method for Design of Oligomer-Specific Antibodies. <i>PLoS ONE</i> , 2014, 9, e90857.	1.1	38
36	Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism. <i>PLoS ONE</i> , 2014, 9, e113387.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Could miRNA expression changes be a reliable clinical biomarker for Parkinson's disease?. Neurodegenerative Disease Management, 2013, 3, 455-465.	1.2	6
38	Cross-camera comparison of ROI-based semi-quantitative <sup>123</sup> I-IBZM SPECT data in healthy volunteers using an anthropomorphic phantom for calibration. Acta Radiologica, 2013, 54, 549-556.	0.5	0
39	The robust electrochemical detection of a Parkinson's disease marker in whole blood sera. Chemical Science, 2012, 3, 3468.	3.7	72
40	Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population-based study. Movement Disorders, 2010, 25, 341-348.	2.2	111